PMID- 34700142
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20220310
IS  - 2468-2942 (Electronic)
IS  - 2468-2942 (Linking)
VI  - 29
DP  - 2021
TI  - Stereotactic body radiation therapy (SBRT) for patients with 
      oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities 
      profile in a monoinstitutional study.
PG  - 100481
LID - S2468-2942(21)00177-5 [pii]
LID - 10.1016/j.ctarc.2021.100481 [doi]
AB  - AIMS: To evaluate survival outcomes and toxicology profiles in 
      oligometastatic/oligoprogressive patients treated with SBRT for adrenal 
      metastases. METHODS: We retrospectively analyzed 25 metastatic adrenal lesions in 
      24 oligometastatic/oligoprogressive patients undergoing ablative Stereotactic 
      Body Radiation Therapy (SBRT) between February 2010 and November 2019 in our 
      department. The primary endpoint was overall survival (OS). Secondary endpoints 
      were local overall response rate (ORR), acute and late toxicities. RESULTS: The 
      most common primary tumor was non-small cell lung cancer (54%). Twenty-one 
      patients received chemo or immuno-therapy. The median planning target volume 
      (PTV) was 41.7 cm(3). Median SBRT dose was 36 Gy. Median dose per fraction was 
      15 Gy. Median survival was 35-months with OS outcomes ranging from 6-months 
      (100%), 1-year (87.5%) and 2-years (66.7%). ORR based on RECIST criteria was 
      66.5%. 12 patients experienced acute toxicities, mostly grade 1-2 (8 patients, 
      32%). CONCLUSIONS: SBRT for oligometastatic/oligoprogressive patients with 
      adrenal metastases showed acceptable survival outcomes and a safe toxicity 
      profile.
CI  - Copyright (c) 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Facondo, Giuseppe
AU  - Facondo G
AD  - Department of Medicine and Surgery and Translational Medicine, Sapienza 
      University of Rome, Radiotherapy Oncology, St Andrea Hospital, Rome, Italy.
FAU - Vullo, Gianluca
AU  - Vullo G
AD  - Department of Medicine and Surgery and Translational Medicine, Sapienza 
      University of Rome, Radiotherapy Oncology, St Andrea Hospital, Rome, Italy. 
      Electronic address: gianluca.vullo@uniroma1.it.
FAU - Valeriani, Maurizio
AU  - Valeriani M
AD  - Department of Medicine and Surgery and Translational Medicine, Sapienza 
      University of Rome, Radiotherapy Oncology, St Andrea Hospital, Rome, Italy.
FAU - Ascolese, Anna Maria
AU  - Ascolese AM
AD  - Department of Medicine and Surgery and Translational Medicine, Sapienza 
      University of Rome, Radiotherapy Oncology, St Andrea Hospital, Rome, Italy.
FAU - De Sanctis, Vitaliana
AU  - De Sanctis V
AD  - Department of Medicine and Surgery and Translational Medicine, Sapienza 
      University of Rome, Radiotherapy Oncology, St Andrea Hospital, Rome, Italy.
FAU - Osti, Mattia Falchetto
AU  - Osti MF
AD  - Department of Medicine and Surgery and Translational Medicine, Sapienza 
      University of Rome, Radiotherapy Oncology, St Andrea Hospital, Rome, Italy.
LA  - eng
PT  - Journal Article
DEP - 20211021
PL  - England
TA  - Cancer Treat Res Commun
JT  - Cancer treatment and research communications
JID - 101694651
SB  - IM
MH  - Adrenal Gland Neoplasms/*complications/mortality
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Radiosurgery/*methods
MH  - Retrospective Studies
MH  - Survival Analysis
OTO - NOTNLM
OT  - Adrenal metastases
OT  - Oligometastatic
OT  - Oligoprogression
OT  - Radiotherapy
OT  - Stereotactic body radiation therapy
EDAT- 2021/10/27 06:00
MHDA- 2022/03/11 06:00
CRDT- 2021/10/26 20:20
PHST- 2021/09/09 00:00 [received]
PHST- 2021/10/06 00:00 [revised]
PHST- 2021/10/19 00:00 [accepted]
PHST- 2021/10/27 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/10/26 20:20 [entrez]
AID - S2468-2942(21)00177-5 [pii]
AID - 10.1016/j.ctarc.2021.100481 [doi]
PST - ppublish
SO  - Cancer Treat Res Commun. 2021;29:100481. doi: 10.1016/j.ctarc.2021.100481. Epub 
      2021 Oct 21.